Mesothelin (MSLN) is a differentiation antigen that is highly expressed in many epithelial cancers. MSLN is an important therapeutic target due to its high expression in cancers and limited expression in normal human tissues. Although it has been assumed that shed antigen is a barrier to immunotoxin action, a modeling study predicted that shed MSLN may enhance the action of MSLN targeting recombinant immunotoxins such as SS1P and similar therapeutics by facilitating their redistribution within tumors. We aimed to determine if shed MSLN enhances or reduces the anti-tumor effect of MSLN targeting immunotoxins SS1P and RG7787. We engineered a cell line, A431/G9 (TACE mutant) that expresses a mutant form of MSLN in which the tumor necrosis factor converting enzyme protease site is replaced with GGGS. We compared the response of the TACE mutant cells to immunotoxins SS1P and RG7787 with that of the parental A431/H9 cell line. We show that TACE mutant cells shed 80% less MSLN than A431/H9 cells, that TACE mutant cells show a 2-3-fold increase in MSLN targeted immunotoxin uptake, and that they are about 5-fold more sensitive to SS1P killing in cell culture.
Introduction
Mesothelin (MSLN) is a cell surface protein that is highly expressed in mesothelioma and many other epithelial cancers. Furthermore, small amounts of MSLN have been observed in the blood of patients with mesothelioma and ovarian cancer (1) . MSLN has limited expression on normal tissues; its expression is limited to mesothelial cells lining the peritoneum, pericardium, and pleura (2) (3) (4) (5) . MSLN does not appear to have a critical function in development, because inactivation of both copies of the MSLN gene in mice does not lead to an overt phenotype (6) .
However it does appear to have a role in cancer growth and progression making it an attractive therapeutic target for antibody-based therapies of cancer (7, 8) .
Antibody based therapies such as antibody drug conjugates and recombinant immunotoxins (RITs) are being developed for the treatment of solid tumors (9). However penetration of these agents into solid tumors is restricted by many factors. Impediments include defective capillaries, slow entry by diffusion because of the lack of functional lymphatics, increased extracellular matrix deposition (10) and high interstitial fluid pressure (11) . It has also been proposed that shed antigen within tumors is another barrier to tumor penetration (12) .
Overcoming these barriers could significantly improve the efficacy of antibody-based therapies.
There are several anti-cancer agents in various stages of development that target MSLN.
These include amatuximab (13, 14) , antibody drug conjugates (15, 16) and . RITs are chimeric proteins composed of an Fv or Fab fused to a portion of Pseudomonas exotoxin A (PE). SS1P is a RIT in which the disulfide-stabilized Fv of a high affinity antibody to MSLN is fused to a 38kDa fragment of PE (17). SS1P kills target cells by inhibiting protein synthesis and activating apoptosis (18, 21) . SS1P is very active in killing MSLN-expressing cancer cell lines (17) and has shown anti-tumor activity in mouse xenograft models (22, 23) . In human studies, MCT-15-0863R 4 SS1P has been found to enhance the anti-tumor activity of chemotherapy agents, gemcitabine, and pemetrexed/cis platinum (23, 24) . When combined with immunosuppressive agents, pentostatin and cyclophosphamide, it produced major remissions in several patients with advanced chemotherapy-refractory mesothelioma (25) . A new anti-MSLN RIT, RG7787 has been recently developed. RG7787 is a clinically optimized anti-MSLN immunotoxin (20) . It is designed to be less immunogenic than SS1P. It also contains mutations that remove or suppress many B cell epitopes and some T cell epitopes and is very cytotoxic to several MSLN-expressing cancers (19) MSLN is shed into the extracellular space of tumors and its levels are elevated in the blood of patients with mesothelioma and ovarian cancer (26) . Antigen shedding is a well recognized process associated with malignant cells (27) . Previous studies from our group have suggested that shed MSLN within the tumor is a barrier to effective therapy with SS1P, because treatment of MSLN-expressing tumors with chemotherapy lowered MSLN levels in the tumor, which allowed more SS1P to reach the tumor cells and enhanced the anti-tumor activity of SS1P (10, 11) . We have also shown that MSLN is released from cells by the action of the tumor necrosis factor converting enzyme (TACE) protease (28) and that inhibition of the protease by an inhibitor or knock down of the TACE protease by siRNA diminishes MSLN shedding and enhances immunotoxin killing of cultured cells (28) . These data suggest that shed MSLN should act as a barrier to the killing of cells by SS1P or related immunotoxins. The current study was designed to establish the role of MSLN shedding in the response of tumors to SS1P and RG7787. To examine the effect of MSLN shedding we constructed a cell line with reduced shedding of MSLN due to a specific deletion of the TACE protease site in MSLN. We find that cells that shed less MSLN are more sensitive to MSLN killing in culture and that tumors derived from these cells shed less MSLN into the blood and are much more sensitive to the anti-tumor effects of SS1P and RG7787.
Materials and Methods

Reagents
SS1P was purified in our laboratory as described previously (30) . Clinical grade RG7787 was manufactured by Roche Innovation Center, Penzberg, Germany. Alexa-labeled RG7787 was made using an Alexa labeling kit from Invitrogen. HB21(Fv)-PE40 immunotoxin was made in our lab. Anti-MSLN (mouse) was purchased from Rockland Immunochemicals (code# 200-301-A88), GAPDH (rabbit mAb 14C10; Product #2118) from Cell Signaling Technology, Goat anti- 
Construction of plasmid expressing mutant MSLN
The expression plasmid pMSLN del (586-593) was generated by the Protein Expression Laboratory (Frederick Core Facility at NCI) using Gateway cloning technology. To try and maintain the native domain structure, the TACE cleavage site (YLVLDLSV) was replaced by a small flexible linker (GGGGS). The resulting clone was then used to generate the mammalian expression vector with a CMV promoter and a neomycin selectable marker.
Generating A431 cells expressing mutant MSLN
On day one, 5x10 
MSLN surface expression
To quantify surface MSLN expression, 5x10 5 cells were trypsinized and harvested. Cells were then centrifuged at 2k rpm for 2 minutes, followed by washing once with cold phosphate buffered saline (PBS). Next, cells were washed once with cold FACS buffer (PBS with 5% FBS and 0.02% NaN3). After centrifuging, cells were re-suspended in 100 μl of FACS buffer Surface staining using labeled RG7787 was described previously (32). Briefly, 2.5x10 5 cells were plated in 6 well Falcon tissue culture plates in 2 ml media. The next day cells were incubated in 500 μl of complete media containing 2 μg of Alexa-647 labeled RG7787 for 45 minutes on ice. Cells were washed twice with PBS followed by addition of 500 μl of trypsin and then placed in an incubator for 2 minutes. Afterwards, 1.5 ml of cold media was added and then transferred into tubes and centrifuged for 2 minutes at 2k rpm. Cells were washed twice with Cell viability is expressed in reference to control where SS1P was not added.
Western blot analysis
Cells were washed in PBS and lysed in lysis buffer on ice for 30 minutes. After 5 minutes centrifugation at 13k rpm, 15 μg of supernatants were loaded in a 4-12% gradient gel and separated by SDS-PAGE under reducing conditions then transferred to polyvinylidene difluoride membranes. The membranes were incubated with MSLN antibody (1:1000) overnight in the cold room. The next day goat-anti-mouse IgG HRP 2° Ab (1:5000) was applied for 1 hour at room temperature followed by washing, then incubation with ECL and exposure to X-ray film.
MSLN shedding assay in vivo and in vitro
Soluble MSLN levels in cell line medium were measured in duplicate with a human MSLN ELISA Kit (Novatein Biosciences). Cells (5x10 5 ) were seeded in 2 ml RPMI cell culture medium in multiwell 6-well polystyrene Falcon tissue culture dishes. The next day media was removed and replaced with 1 ml of fresh media. Every hour thereafter, 100 μl of medium was collected and stored in −80°C. Other plates remained in the incubator for 4 days and afterwards, media was collected and stored at −80°C. Cells were trypsinized and counted using a cell A431/H9 or A431/G10 TACE mutant cells on day 1; two mice were used as controls.
When tumors reached 300-500mm 3 , blood was collected from each mouse and transferred into heparin-coated tubes. Samples were centrifuged for 15 minutes at 1000g, plasma was collected and aliquoted into new heparin coated tubes and stored at -80°C. For MSLN ELISA assays, samples were diluted and analyzed.
In vitro immunotoxin internalization and FACS analysis
Wild-type and TACE mutant cells (2.5x10 5 ) were seeded in a multiwell 6-well tissue culture dishes. After 16-20 hours, cells were exposed to 10 ng/ml of RG7787-Alexa Fluor 647 in 1 mL of media for 90 minutes and for 4, 8, 16, and 24 hours. Surface bound RG7787-Alexa Fluor 647 was stripped for 5 minutes using a low pH glycine buffer (0.2 mol/L glycine-HCl, pH 2.5) and 1% BSA to remove surface-bound RG7787. Cells were then trypsinized, washed with cold internalization-FACS buffer (PBS with 1% FBS and 0.1% NaN3) twice, then resuspended in 500 μl cold FACS buffer and analyzed using FACSCanto II. Quantification of internalized RG7787 molecules was performed as described previously (32). For surface staining, cells were either detached using trypsin or citric saline for comparison. Cells were treated with 2 μg/ml of labeled immunotoxin for 45 minutes on ice. 
Statistical analysis
Data were analyzed and statistical analyses were performed using GraphPad Prism 6 software and Excel. Each experiment was performed at least twice and we used duplicates or triplicates for each point in every assay. Data are presented either as mean ± SD or ± SEM.
Unpaired student test and one-way analysis of variance (ANOVA) with Mann-Whitney test for comparisons was performed. A p-value of <0.05 was considered statistically significant. 
Results
Generation
MCT-15-0863R 11 equal expression, we constructed a plasmid with a deletion of the TACE protease site (Fig. 1A) and stably transfected it into A431 cells. After antibiotic selection and cell sorting we isolated several clones with high MSLN expression. We chose clone A431/G9 for further analysis, although several other clones have the same expression level. Flow cytometry analysis shows that clone A431/G9 has high MSLN expression that is comparable to that of A431/H9 cells ( Fig.   1B and Supplementary Fig. S1) . We measured the level of surface MSLN expression by two different methods. First, we used RG7787 directly labeled with Alex-647 (Fig. 1B) . Next we used an anti-MSLN antibody followed by a fluorescently-labeled secondary antibody ( Supplementary Fig. S1 ). Both analyses showed that the level of MSLN expression was very similar in A431/H9 and TACE mutant cells. MSLN expression was also analyzed by western blots, and the results revealed a slight but statistically insignificant increase in total MSLN protein expression in TACE mutant cells (Fig. 1C and 1D) . Figure 1B shows that wild-type and TACE mutant cells have similar MSLN surface expression. To determine whether both cell lines saturate at the same concentrations of RIT, equal numbers of wild-type and mutant cells were plated overnight and the next day cells were detached using trypsin reagent. Cells were washed and exposed to increasing concentrations of labeled RG7787 on ice for 45 minutes and then flow cytometry was performed. As shown in Figure 2A , both cell lines saturate at the same concentrations.
Comparison of MSLN expression in A431/H9 and TACE mutant cells
Trypsin is known to remove surface proteins and might affect our data due to variability of trypsinization time. To be certain that there are similar amounts of MSLN molecules of both cell lines, we repeated our FACS experiments using citric saline to remove cells because it acts 
non-enzymatically to detach cells. We then treated cells with increasing concentrations of labeled RG7787. Our results show that both cell lines express similar amounts of MSLN and also saturate at the same concentration (Fig. 2B) .
To determine the effect of the TACE deletion on MSLN shedding, we collected media from growing cells and performed an ELISA assay to measure MSLN levels. The MSLN concentration was 831 ng/ml in the A431/H9 medium and 160 ng/ml in the medium from TACE mutant cells indicating a major decrease in MSLN shedding (Table 1 ). This data indicates shedding was greatly decreased but not completely abrogated. Next we investigated and compared the amount of MSLN shed per cell per hour over a 6-hour period by wild-type and mutant cells. The data is presented in Figure 2C and Table 2 . The wild-type cells have shed more than 100% of the total on the surface at 1 hour and continue to shed at this high rate for 6 hours.
In contrast, the cells shed much less MSLN with the TACE site deleted,. After 1 hour, wild-type cells had shed all their surface MSLN, while mutant cells shed only 27% (Table 2 ).
In some cell lines MSLN has been shown to regulate cancer cell growth and proliferation (37, 38) . To determine if the decrease in MSLN shedding by mutant cells affected the growth of the cells, we measured cell number over several days and found no change in growth rate between wild-type A431/H9 and TACE mutant cells (Fig. 2D) . Based on these data we conclude the cell lines were suitable for additional comparative studies.
Sensitivity of TACE mutant cells to SS1P, RG7787, and HB21(Fv)-PE40
To determine if decreased MSLN shedding had an impact on the efficacy of MSLNtargeting immunotoxins in vitro, we treated wild-type and TACE mutant cells with SS1P and RG7787. As shown in Figure 3A and MCT-15-0863R 13 SS1P than A431/H9 cells (0.01 ng/ml compared to 0.05 ng/ml), respectively. The TACE mutant was also about 3.5-fold more sensitive to RG7787 than A431/H9 cells (0.16 ng/ml compared to 0.62 ng/ml), respectively ( Fig. 3B and Table 1 ). To show that the difference in the cytotoxic effect was MSLN-specific, we treated the cell lines with an immunotoxin targeted to the human transferrin receptor, HB21(Fv)-PE40 (20) and found no difference in its effect on the two cell lines indicating the difference is MSLN-specific as shown in Figure 3C .
Uptake of RG7787 by TACE mutant and A431/H9 cells
Because TACE mutant cells were more sensitive to SS1P and RG7787 than A431/H9 cells, we examined their rate of uptake of immunotoxn assuming that shedding would reduce uptake. To do this, cells were seeded in 6-well dishes and 16 hours later 10 ng/ml of RG7787-Alexa Fluor 647 was added and cells harvested after 90 minutes, 4, 8, 12, and 16 hours. As shown in Figure 4 , there was a 2-fold increase in uptake at all time points by TACE mutant cells compared to wild-type cells.
Sensitivity of TACE mutant tumors to immunotoxins SS1P, RG7787 and HB21-(Fv)-PE40
The data in Table 1 shows that that TACE mutant cells shed 5-fold less MSLN than wildtype cells. Next, we investigated the levels of circulating shed MSLN in wild-type and TACE mutant mouse xenograft models. To do this we collected blood from mice with wild-type and TACE mutant tumors and analyzed the plasma using a MSLN-specific sandwich ELISA kit. Our results show greater than 20-fold less MSLN in the plasma of mice with TACE mutant tumors compared to wild-type tumors (Fig. 5A) . Next, we carried out anti-tumor experiments in mice to test the mathematical model. We implanted 2x10 To confirm our finding with SS1P, we examined the anti-tumor efficacy of RG7787 on A431/H9 and TACE mutant tumors. Although RG7787 is more active than SS1P on many epithelial cancers (20) , it is less active on A431/H9 cells as shown in Table 1 , and therefore larger doses were used in mice. TACE mutant tumors treated with 50 μg given QODx3 were also much more responsive to RG7787 than A431/H9 tumors (Fig. 5C ). Similar to the SS1P antitumor study, there was a statistically significant difference in the size of the TACE mutant tumors after RG7787 treatment compared to A431/H9 tumors beginning on day 9 (p<0.0001), and the difference in tumor size continued to be significant for the remainder of the experiment.
To show that the difference in response to immunotoxin treatment was related to MSLN shedding and not to some other difference in the tumors, we also treated the A431/H9 and TACE mutant tumors with HB21(Fv)-PE40 that targets the human transferrin receptor and observed no difference in response (Fig. 5D) 
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vitro results. We conclude that the difference in the anti-tumor effect is specific for the anti-MSLN immunotoxins and directly correlate with MSLN shedding.
Discussion
It is well known that many proteins that are targeted by antibody-based therapies are shed from the cell surface. This shed antigen has the potential to act as a decoy receptor and inhibits the action of these agents. However, because solid tumors are not in direct communication with the blood, and because immunotoxin SS1P took many hours after its entry into tumors to reach the maximum number of cells in the tumor, we carried out mathematical analysis of our data, which unexpectedly predicted that antigen shedding should enhance and not block the efficacy of RITs that target MSLN-expressing tumors (29) . This report suggested that shed antigen acts as a protective reservoir, which carries RITs into spaces far from the blood vessel.
In this study, our goal was to utilize both in vitro and animal studies to test this mathematical model. To do this, we generated and characterized a cell line, A431/G9 (TACE mutant), which expresses a mutant form of MSLN that lacks the TACE sheddase site. We performed several experiments to make sure the mutant cells were characteristically similar to wild-type cells. Flow cytometry and cell culture experiments showed both wild-type and mutant cells displayed similar numbers of MSLN sites per cell and similar growth rates. We also show that both wild-type and mutant cells saturate at the same antibody concentration. It was previously shown that knockdown of TACE led to greater than 50% inhibition of MSLN shedding (28) . These results suggested that TACE was a major MSLN-cleaving protease, however there are other enzymes that cleave MSLN because knockdown of TACE did not completely abrogate MSLN shedding. We tested for MSLN shedding into cultured media and in The findings presented here indicate that there are factors that are more important in regulating immunotoxin action than the binding site barrier effect. One possibility is that the immunotoxin action is hindered more by a low endocytosis rate than by possible binding site barrier effect. The endocytosis rate used in the mathematical model we reported previously (29, 39) was 22% per hour, which was derived by analyzing earlier in vitro data (40) . The binding site barrier effect is the dominant factor for this model and the efficacy of immunotoxins increases monotonically as the shedding rate increases when the number of receptor molecules is one million or more. However, when the endocytosis rate is reduced to 8%, the immunotoxin is less effective in the tumor model with 20% shedding rate than those with 1.5% or 5% shedding rate. Thus, one possibility is that the in vivo endocytosis rate is much less than that measured in in vitro experiment in which case increasing the uptake rate by reducing shedding becomes beneficial rather than a barrier.
In conclusion, our results suggest that strategies that prevent MSLN shedding may significantly enhance immunotoxin efficacy in the treatment of MSLN-expressing cancers. Mouse 4=567ng/ml; Mouse 5= 469.3ng/ml; TACE mutant mouse 1=31ng/ml; Mouse 2=27.2ng/ml; Mouse 3=25ng/ml; Mouse 4=8.3ng/ml; Mouse 5=30ng/ml) were pooled between Reduced MSLN shedding leads to increased internalization of Alexa-647 labeled RG7787
immunotoxin. Cells were incubated with 10 μg/ml of Alexa-647-RG7787 and uptake measured. 
